3^rd conference on Conference on Drug Discovery & Drug Design:

ChemBio Interactions

ChemBioInteract

The first Conference ChemBioInteract took place in Saarbruecken (Germany), on May 24-25, 2012. It was organized inside Interreg IV-A and Corena networks, with the supports of Redcat and Universität des Saarlandes (Pr. Claus Jacob). This first Conference was entitled “ChemBio on Metals and Enzymes. Focus on Trafficking, Chelating and Inhibiting”.

The Unit Research EA 4446 Biomolecules Cancer Chemoresistances (B2C) and the Cancer Research Center of Lyon (CRCL) organized the second Conference ChemBioInteract “Drug Discovery & Drug Design: ChemBio Interactions“ on October 3-4, 2013. This Conference was localized at Villeurbanne (La Doua Campus, University Claude Bernard Lyon 1), in partnership with the Region Rhône-Alpes and the “Association Lyonnaise France Allemagne” (ALFA), and under the kind patronage of Mr. Dr. Christian SEEBODE, Consul General of the Federal Republic of Germany in Lyon. It was organized as part of the celebration of the 50^th anniversary of the Elysée Treaty.

On 2015 (August 26-27), the third Conference ChemBioInteract will be organized together with the 23^rd Conference of GP2A under the joint header 1^st European Conference on Therapeutic Targets and Medicinal Chemistry (TTMC 2015).

 

The conference will discuss the main themes developed in the field of Drug Discovery and Drug Design, with a focus on molecular modeling, chemistry of bioactive molecules and their molecular diversity, pharmacodynamics, technological advances for drug discovery of new drugs and vectorization of therapeutic agents.

The main objectives of the Conference ChemBioInteract are to promote talks between the Rhone-Alps researchers and German and Scandinavian researchers, to develop or/and to strengthen a network of partners in the forthcoming national and european plans (research 2016-2020 State contract, calls for transnational projects, Horizon 2020…).

This Conference is aimed at researchers and actors interested by therapeutic innovation, at the interface ChemBio.